AI Article Synopsis
Article Abstract
54-year-old male was introduced to our hospital in January 2012 for surgical treatment and chemotherapy. The pathological examination revealed well differentiated squamous cell carcinoma of the penis. Computed tomography and magnetic resonance imaging indicated right inguinal and pelvic lymphadenopathy. We diagnosed the tumor to be unresectable radically and administered paclitaxel, cisplatin and 5-fluorouracil (TPF) as neoadjuvant chemotherapy. After 3 courses of chemotherapy, the size of lymphadenopathy had become small enough to allow curative surgical treatment. Partial penectomy and lymph node dissection were performed after neoadjuvant chemotherapy. For 12 months after this radical treatment, the patient has been healthy with no local resurrence and no distant metastatic lesion. TPF chemotherapy for unresectable nodal metastasis from squamous cell carcinoma of penis was suggested to be effective.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Taiwan J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address:
Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Materials And Methods: We retrospectively reviewed patients with stage IVB cervical cancer who received paclitaxel-cisplatin-bevacizumab as first-line treatment between July 2015 and December 2021 at Asan Medical Center, Korea. Patient data including clinicopathologic characteristics, imaging, paclitaxel-cisplatin-bevacizumab administration, recurrence, and survival were collected.
The surgical safety margin after neoadjuvant chemotherapy combined with nimotuzumab leading to tumor regression.
J Chin Med Assoc
December 2024
Department of Stomatology, The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital, Hebei, China.
Background: To investigate the effect of nimotuzumab (N) combined with nab-paclitaxel, cisplatin, and fluorouracil (APF) neoadjuvant chemotherapy on the surgical margin.
Methods: 55 patients were divided into three groups: neoadjuvant chemotherapy and surgery group (G1, 15 cases), chemotherapy and surgery group (G2 group, 20 cases), and surgery group (G3 group, 20 cases). Tissue samples of the tumor core zone (P0), adjacent (P1, 3-5mm from tumor), distal adjacent (P2, 7-10mm from tumor), and surgical margin (P3, 15mm from tumor) were collected.
CD8 + T-Cell-Related Genes: Deciphering Their Role in the Pancreatic Adenocarcinoma TME and Their Effect on Prognosis.
Dig Dis Sci
November 2024
Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No. 59 Haier Road, Qingdao, 266000, Shandong, China.
Article Synopsis
- Immunotherapy and targeted therapies struggle to effectively treat pancreatic adenocarcinoma (PAAD) due to its unique tumor microenvironment (TME), highlighting the importance of CD8+ T cells in this context.
- * Researchers utilized gene coexpression network analysis and algorithms to assess PAAD data from The Cancer Genome Atlas, aiming to understand CD8+ T-cell infiltration and develop a risk score model for patient prognosis.
- * A validated risk model, based on five CD8-related genes, indicated that patients in a low-risk group had better survival outcomes, while also finding correlations between tumor mutation burden and immune function associated with the risk score.
Diaphragm epithelioid hemangioendothelioma: a rare case report.
BMC Geriatr
November 2024
Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, The Second Clinical Medical College, Chengdu Fifth People's Hospital, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Article Synopsis
- * A case study details a 75-year-old male with symptoms like cough and chest tightness who was diagnosed with Diaphragm EHE after a biopsy, and despite receiving chemotherapy and targeted therapy treatment, he experienced disease progression.
- * The study concludes that EHE associated with pleural effusion tends to progress rapidly, indicating challenges in managing such cases.
Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.
J Dermatol
January 2025
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICIs), like pembrolizumab (PEM), are effective against tumors but can cause serious skin side effects (cutaneously adverse events or CAEs), especially when used in combination therapies.
- Severe CAEs may require stopping the immunotherapy, and the risk is higher when ICIs are used with other treatments compared to when they are used alone.
- A case study of 19 women with advanced cervical cancer highlighted the occurrence of severe CAEs, including erythema multiforme and anaphylaxis, stressing the need for tight monitoring of skin reactions during PEM combination therapy to ensure patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!